Vericel Corp VCEL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
7/9
Piotroski F — financial health
3.1
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $276.3M | $16.5M | $205.6M | $24.7M | $354.6M |
| 2024 | $237.2M | $10.4M | $172.1M | -$5.8M | $292.0M |
| 2023 | $197.5M | -$3.2M | $135.6M | $15.3M | $226.0M |
| 2022 | $164.4M | -$16.7M | $109.8M | $10.1M | $192.3M |
| 2021 | $156.2M | -$7.5M | $106.0M | $21.1M | $170.5M |
| 2020 | $122.0M | $2.9M | $84.2M | $14.9M | $134.3M |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.1 (safe)
- Working capital / assets 0.406
- Retained earnings / assets -0.771
- EBIT / assets 0.023
- Equity / liabilities 2.66
Source: SEC EDGAR filings · CIK 0000887359 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.